Excessive Daytime Sleepiness
8
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
4
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
2
5
Early DiscoveryClinical DevelopmentMarket
On Market (4)
Approved therapies currently available
U
ARMODAFINILApproved
armodafinil
Unknown Companyoral2016
U
NUVIGILApproved
armodafinil
Unknown Companyoral2007
U
SOLRIAMFETOLApproved
solriamfetol
Unknown CompanySUNOSIApproved
solriamfetol
Axsome TherapeuticsDopamine and Norepinephrine Reuptake Inhibitor [EPC]oral2019
Competitive Landscape
3 companies ranked by most advanced pipeline stage
TevaIsrael - Petach Tikva
2 programs2
ArmodafinilPhase 31 trial
Armodafinil 100 to 250 mg/dayPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Axsome TherapeuticsSolriamfetol
TevaArmodafinil
TevaArmodafinil 100 to 250 mg/day
Centessa PharmaceuticalsORX142 Tablets
Clinical Trials (4)
Total enrollment: 1,257 patients across 4 trials
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
Start: May 2021Est. completion: Sep 202259 patients
Phase 4Completed
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
Start: Oct 2005Est. completion: Jul 2006247 patients
Phase 3Completed
Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness
Start: May 2004Est. completion: Jul 2006743 patients
Phase 3Completed
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
Start: Jun 2025Est. completion: Jun 2026208 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,257 patients
3 companies competing in this space